{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-004485","form_type":"8-K","ticker":"SRZN","cik":"0001824893","company_name":"Surrozen, Inc./DE","filed_at":"2022-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.568445+00:00","generated_at":"2026-06-26T18:46:10.136421+00:00","sec_items":["2.02","5.08","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Surrozen reports full-year 2021 net loss of $47.3M; on track for Phase 1 starts in Q3 2022","bullets":["FY2021 net loss $47.3M vs $20.4M in 2020; R&D expenses $35.5M.","Cash and equivalents $137.8M as of Dec 31, 2021.","Phase 1 trials for SZN-1326 (ulcerative colitis) and SZN-043 (alcoholic hepatitis) expected to start Q3 2022.","Nominated SZN-413, a Fzd4 bi-specific antibody, for retinal vascular diseases including wet AMD.","2022 Annual Meeting set for June 7, 2022; record date April 11, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-004485","json":"https://secwatch.observer/filing/0000950170-22-004485.json","markdown":"https://secwatch.observer/filing/0000950170-22-004485.md","text":"https://secwatch.observer/filing/0000950170-22-004485.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824893/000095017022004485/0000950170-22-004485-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824893/000095017022004485/srzn-20220321.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T18:46:10.136421+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}